Investors & Media

Webcast ImageWebcast
Q2 2016 Ionis Pharmaceuticals Inc Earnings Conference Call (Live)
08/09/16 at 11:30 a.m. ET
Q2 2016 Ionis Pharmaceuticals Inc Earnings Conference Call
Tuesday, August 9, 2016 11:30 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Company Profile
We are the leading company in RNA-targeted drug discovery and development with a pipeline of first-in-class or best-in-class medicines with the potential to provide high value for patients with significant unmet medical needs. We have created an efficient and broadly applicable drug discovery platform. Using this platform, we believe that we are revolutionizing medicine with the goal to improve the quality of, and save, lives.
Recent Press ReleasesMore >>
07/28/16Akcea Therapeutics Receives Orphan Designation in Europe for Volanesorsen for the Treatment of Familial Partial Lipodystrophy (FPL)
CAMBRIDGE, Mass., July 28, 2016 /PRNewswire/ -- Akcea Therapeutics, a wholly-owned subsidiary of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), announced today that the European Commission (EC) has designated volanesorsen as an orphan medicinal product for the treatment of familial partial lipodystrophy (FPL).  FPL is a rare lipid disorder characterized by abnormal fat distribution across the body and a range of metabolic abnormalities, including severe type 2 diabetes, high triglycerides, and accu... 
Printer Friendly Version
07/26/16Webcast Alert: Ionis Pharmaceuticals' Second Quarter 2016 Financial Results Conference Call
- Webcast scheduled for Tuesday, August 9 at 11:30 a.m. Eastern Time CARLSBAD, Calif., July 26, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Tuesday, August 9 at 11:30 a.m. Eastern Time to discuss its second quarter 2016 financial results, and report on pipeline and business progress. Interested parties may listen to the call by dialing 877-443-5662 or access the webcast at A webcast replay will b... 
Printer Friendly Version
07/19/16Ionis Pharmaceuticals Licenses First Oral Antisense Drug Acting Locally in the GI Tract to Janssen
CARLSBAD, Calif., July 19, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it has earned $10 million from Janssen Biotech, Inc. (Janssen) upon licensing IONIS-JBI1-2.5Rx, an orally delivered antisense drug designed to locally inhibit an undisclosed target in the gastrointestinal (GI) tract for the treatment of a GI autoimmune disease.  Janssen will assume all global development, regulatory and commercialization responsibilities for IONIS-JBI1-2.5Rx once Ionis... 
Printer Friendly Version
07/12/16Ionis Pharmaceuticals Announces Publication in Nature Biotechnology of a Novel Mechanism of Action for Antisense Drugs That Significantly Expands Therapeutic Opportunities
-Innovative New Mechanism Allows Antisense Drugs to Increase the Production of Specific Proteins By Up to 150%- CARLSBAD, Calif., July 12, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the publication of new research findings in Nature Biotechnology describing a new mechanism of action for antisense technology, which further expands the potential reach of antisense technology.  The paper entitled "Translation efficiency of mRNAs is increased by antisense olig... 
Printer Friendly Version
Upcoming EventsMore >>
08/09/16 11:30 a.m. ET
Q2 2016 Ionis Pharmaceuticals Inc Earnings Conference Call

For more information requests, please visit our Information Request page.

If you are interested in Ionis Pharmaceuticals’ investment details,
please visit our Investor FAQ page.

Data provided by Nasdaq. Minimum 15 minutes delayed.